TITLE

Zadowolenie pacjentów z leczenia przeciwłuszczycowego: wyniki badania PSO Survey w Polsce

AUTHOR(S)
Szepietowski, Jacek; Reich, Adam; Palotai, Tamás; Kaszuba4, Andrzej; Chodorowska, Grażyna; Brzezińska-Wcisło, Ligia; Rudnicka, Lidia; Giemza, Tomasz
PUB. DATE
September 2009
SOURCE
Clinical Dermatology / Dermatologia Kliniczna;2009, Vol. 11 Issue 3, p129
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Psoriasis is a chronic, inflammatory skin disorder affecting about 1-3% of general population. Currently available treatment modalities enable to achieve remission of psoriasis, however, the complete cure of this disease is still not possible. Objective: The aim of the study was the assessment of patient satisfaction from current antipsoriatic therapy and an attempt to characterise parameters, that would enable to define high-need patients. Material and methods: A total of 210 patients suffering from psoriasis aged between 18 and 86 years (mean: 47.9±15.2 years) were recruited. A specially designed questionnaire with questions about clinical manifestation of psoriasis, currently applied treatment, and patient satisfaction and preferences regarding the antipsoriatic therapy was completed based on anamnesis and physical examination. All results were analysed statistically. Results: The mean severity of psoriasis according to PASI was 13.0±8.9 points (range 1-58 points), and the mean body surface area affected by psoriasis was 28.2±19.7% (range 2-99%). Among all included subjects, 85 (40.5%) patients were not satisfied with the current antipsoriatic treatment. Subjects with joint involvement (57.9% vs. 36.6%, p=0.03), scalp psoriasis (45.6% vs. 28.6%, p=0.03) and treated with coal tar products (62.5% vs. 35.3%, p<0.01), anthralin (50% vs. 23%, p<0.001), or methotrexate (57.9% vs. 36.6%, p=0.03) were more commonly dissatisfied with the antipsoriatic therapy. Dissatisfied patients also suffered from more severe (PASI: 15.9±9.5 points vs. 11.1±7.9 points, p<0.001) and more extensive psoriasis (BSA: 32.9±20.9% vs. 25.0±18.2%, p<0.001) and had more severely impaired quality of life (DLQI: 13.3±5.3 points vs. 9.4±6.2 points, p<0.001). Conclusions: Many Polish patients suffering from psoriasis are dissatisfied with the applied antipsoriatic treatment. It could be supposed, that better accessibility of Polish patients to the newest antipsoriatic therapies would improve the degree of patient satisfaction with the treatment of psoriasis.
ACCESSION #
48679583

 

Related Articles

  • Risk-Benefit Assessment of Methotrexate in the Treatment of Severe Psoriasis. Kuijpers, A.L.; van der Kerkhof, P.C.M. // American Journal of Clinical Dermatology;Jan/Feb2000, Vol. 1 Issue 1, p27 

    Methotrexate is an established and highly effective systemic treatment for severe psoriasis, including the pustular and erythrodermic forms. It has been widely used during the last 3 decades. For this reason, the long term adverse effects of methotrexate are well known, in contrast to other...

  • BJD Editor's Choice.  // Journal of Investigative Dermatology;Oct2012, Vol. 132 Issue 10, p2310 

    The article offers information related to the treatment of several skin disorders. It informs that etanercept plus methotrexate can be a viable regimen in the patients suffering from psoriasis. It further states that using oral tofacitinib for treating psoriasis results a significant clinical...

  • Therapeutics.  // Current Medical Literature: Dermatology;2009, Vol. 14 Issue 3, p62 

    The article presents updates on the treatment of skin diseases. An updated guideline for the use of methotrexate in the treatment of psoriasis was released by the Medical Board of National Psoriasis Foundation. Systemic corticosteroids were considered as mainstays for the treatment of chronic...

  • Psoriasis: Flaky is only an adjective for piecrusts. Schaefer, Ingrid K. // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS3 

    Editorial. Contemplates on the advances in psoriasis care. Effectiveness of over-the-counter remedies on psoriasis; Challenge for manufacturers to come up with a more effective treatment for proriasis.

  • FDA okays psoriasis indication for a cyclosporine.  // Dermatology Times;Nov97 Supplement, Vol. 18 Issue 11, pS25 

    Presents highlights of the Neoral labeling related top psoriasis. Considerations before initiating treatment with the drug; Initial recommended dose for patients with psoriasis; Cautions against the use of Neoral for longer than a year.

  • Patient Education Critical Factor in Successful Tazarotene Use. Moore, Ian J.S. // Dermatology Times;Feb98, Vol. 19 Issue 2, p45 

    States that tazarotene can be used successfully as a first-line treatment in psoriatic patients when they are properly instructed about its use. Factors to consider in prescribing the drug for psoriasis treatment; Common side effects of psoriatic treatment; How to manage the side effects of...

  • Psoriasis solution. Segell, Michael // Cosmopolitan;Sep95, Vol. 219 Issue 3, p94 

    Suggests a treatment for the skin disease called psoriasis. Estimated number of Americans afflicted with psoriasis; Cause of disease; Experimental therapy that may lead to discovery of drug for disease.

  • A New Calcipotriol/Betamethasone Formulation with Rapid Onset of Action was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis Vulgaris. Douglas, W. S.; Poulin, Y.; Decroix, J.; Ortonne, J. P.; Mrowietz, U.; Gulliver, W.; Krogstad, A. L.; Larsen, F. G.; Iglesias, L.; Buckley, C.; Bibby, A. J. // Acta Dermato-Venereologica;Mar2002, Vol. 82 Issue 2, p131 

    In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone[sup ®]) and calcipotriol ointment (Daivonex[sup ®]) in patients with psoriasis vulgaris; 1106 patients were randomized to...

  • Oral Tazarotene. Guttman, Cheryl // Dermatology Times;May2003, Vol. 24 Issue 5, p24 

    Focuses on the use of oral tazarotene in treating psoriasis. Side effects of the drug; Mechanism of action.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics